DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Valbenazine
Valbenazine
CDPHP Medicare Advantage 2021 Part D Prior Authorization Criteria
The Effects of Valbenazine in Participants with Tardive Dyskinesia
(Xenazine); Deutetrabenazine (Austedo); Valbenazine
209241Orig1s000
Central Nervous System (CNS) Agents
Medications to Be Avoided Or Used with Caution in Parkinson's Disease
Drug Interactions Mechanisms and Clinical Relevance Jonathan E
Movement Disorders Therapeutic Class Review (TCR)
Corporate Medical Policy Pharmacogenetics Testing AHS – M2021 “Notification”
Valbenazine) Capsules, for Oral Use Biosciences, Inc
2017 New Drug Update
Valbenazine for Tardive Dyskinesia
Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
Clinical Policy: Deutetrabenazine (Austedo)
Pharmacogenetic Considerations For
209241Orig1s000
View Board (#17–0011)
Clinical Policy: Valbenazine (Ingrezza) Reference Number: PA.CP.PHAR.340 Effective Date: 01/18 Last Review Date: 04/19 Revision Log
Top View
Drugs with QT Prolonging Effects (Categorized Into Tdp Risk)
The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study
Ingrezza (Valbenazine)
Pharmacy Prior Authorization Criteria
CP.PHAR.340 Valbenazine (Ingrezza)
WHO Drug Information Vol
Update on Psychiatric Medications
INGREZZA (Valbenazine) RATIONALE for INCLUSION in PA PROGRAM
Continuing Education for Pharmacists Volume XXXVI, No
Psychiatry Pharmacogenetic Genotyping Panel
CVS Caremark® Value Formulary Effective As of 07/01/2021
Ingrezza (Valbenazine) C12649-A
Valbenazine (Ingrezza) Reference Number: CP.CPA.351 Effective Date: 06.01.21 Last Review Date: 05.21 Line of Business: Commercial Revision Log
FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
Non-Preferred Drug List (NPDL)
Ingrezza™ (Valbenazine)
209241Orig1s000
Youscript Comprehensive Medication List
Clinical Policy: VMAT2 Inhibitors (Ingrezza, Austedo, Xenazine)
Small-Cap Research
[email protected]
Youscript Actionable Medication List
Medications to Avoid
FDA Approved VMAT2 Inhibitors for the Treatment of Tardive Dyskinesia
VMAT-2 Inhibitors: Deutetrabenazine, Tetrabenazine And
Gene and Drug Lists
Pharmacy & Therapeutics Committee Meeting
Psychopharmacology: the Basics and Beyond
Generic and Brand Medication Names Purpose Usual Dose and Frequency Potential Side Effects Emergency Conditions Cautions Substance Use Disorders Treatment Medications
Valbenazine (Ingrezza) Reference Number: ERX.SPA.157 Effective Date: 09.01.17 Last Review Date: 05.21 Line of Business: Commercial, Medicaid Revision Log
Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites
Ingrezza Valbenazine Molina Clinical Policy
Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites
Full Prescribing Information for Discontinue INGREZZA Treatment in Patients Who Develop Clinically INGREZZA
Clinical Psychopharmacology for Neurologists
Drug-Induced Movement Disorders
Proposed Formulary Changes Effective 4/1/2018 (Unless Otherwise Noted)